OVID Stock Analysis: Buy, Sell, or Hold?
OVID - Ovid Therapeutics Inc. Common Stock
$2.30
-0.16 (-6.50%)
▼
5d:
-12.21%
30d:
+39.39%
90d:
+29.92%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
OVID is down 5.6% this week, but smart money is accumulating calls. Top strike: $2 2026-04-17 with 631 OI. Call ratio: 89% View Scanner →
Strength: 6.7/10
Get Alerted When OVID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OVID is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OVID is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: OVID is currently trading at $2.30, which is considered slightly high relative to its 30-day fair value range of $1.57 to $2.30.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $1.89, while resistance sits at $2.72. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: OVID has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.55 (+97.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $1.89, while resistance sits at $2.72. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: OVID has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.55 (+97.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$1.57 -
$2.30
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 97.8% below Wall St target ($4.55)
- WARNING: Recommendation downgraded due to -12.2% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.57 -
$2.30
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.89
Resistance Level
$2.72
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.55
Wall Street Target
$4.55
(+97.8%)
Revenue Growth (YoY)
844.7%
Profit Margin
-240.1%
Share & Embed Analysis
Last updated: March 30, 2026 8:55 AM ET
Data refreshes hourly during market hours. Next update: 9:55 AM
Data refreshes hourly during market hours. Next update: 9:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OVID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 42 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 54 HOLD |
